Pharmacogenetic study of seven polymorphisms in three nicotinic acetylcholine receptor subunits in smoking-cessation therapies

[1]  C. Li,et al.  Replicated Risk Nicotinic Cholinergic Receptor Genes for Nicotine Dependence , 2016, Genes.

[2]  S. Steinberg,et al.  Genome-wide meta-analysis reveals common splice site acceptor variant in CHRNA4 associated with nicotine dependence , 2015, Translational Psychiatry.

[3]  Hongyu Zhao,et al.  Genome-Wide Association Study of Nicotine Dependence in American Populations: Identification of Novel Risk Loci in Both African-Americans and European-Americans , 2015, Biological Psychiatry.

[4]  C. la Vecchia,et al.  A Combined Smoking Cessation Intervention within a Lung Cancer Screening Trial: A Pilot Observational Study , 2015, Tumori.

[5]  Megan E. Piper,et al.  Beyond cigarettes per day. A genome-wide association study of the biomarker carbon monoxide. , 2014, Annals of the American Thoracic Society.

[6]  Catherine A. Sugar,et al.  Brain nicotinic acetylcholine receptor availability and response to smoking cessation treatment: a randomized trial. , 2014, JAMA psychiatry.

[7]  L. Bierut,et al.  A glimpse into the future – Personalized medicine for smoking cessation , 2014, Neuropharmacology.

[8]  B. Heckman,et al.  Variation in the Alpha 5 Nicotinic Acetylcholine Receptor Subunit Gene Predicts Cigarette Smoking Intensity as a Function of Nicotine Content , 2013, The Pharmacogenomics Journal.

[9]  R. Perera,et al.  Pharmacological interventions for smoking cessation: an overview and network meta-analysis. , 2013, The Cochrane database of systematic reviews.

[10]  P. Kwok,et al.  Nicotinic acetylcholine receptor variation and response to smoking cessation therapies , 2013, Pharmacogenetics and genomics.

[11]  Prabhat Jha,et al.  21st-century hazards of smoking and benefits of cessation in the United States. , 2013, The New England journal of medicine.

[12]  V. Beral,et al.  The 21st century hazards of smoking and benefits of stopping: a prospective study of one million women in the UK , 2013, BDJ.

[13]  B. Shen,et al.  CHRNA5 polymorphism and susceptibility to lung cancer in a Chinese population , 2013, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[14]  Hsin-Chieh Yeh,et al.  Effect of the 2011 vs 2003 duty hour regulation-compliant models on sleep duration, trainee education, and continuity of patient care among internal medicine house staff: a randomized trial. , 2013, JAMA internal medicine.

[15]  M. Munafo,et al.  Association between nicotinic acetylcholine receptor single nucleotide polymorphisms and smoking cessation. , 2012, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[16]  L. Bierut,et al.  Smoking Cessation Pharmacogenetics: Analysis of Varenicline and Bupropion in Placebo-Controlled Clinical Trials , 2011, Neuropsychopharmacology.

[17]  L. Tanoue.  Quitting Smoking Among Adults — United States, 2001–2010 , 2012 .

[18]  J. Ryu,et al.  Cigarette Smoking and Diffuse Lung Disease , 2012, Drugs.

[19]  Kenneth W Lin,et al.  Nicotine receptor partial agonists for smoking cessation. , 2011, American family physician.

[20]  Steven E. Arnold,et al.  In Vitro and Ex Vivo Analysis of CHRNA3 and CHRNA5 Haplotype Expression , 2011, PloS one.

[21]  Ryan M. Smith,et al.  Nicotinic α5 receptor subunit mRNA expression is associated with distant 5′ upstream polymorphisms , 2011, European Journal of Human Genetics.

[22]  Madison,et al.  Quitting Smoking Among Adults — United States, 2001–2010 , 2012 .

[23]  U. Pastorino,et al.  Promoter polymorphisms and transcript levels of nicotinic receptor CHRNA5. , 2010, Journal of the National Cancer Institute.

[24]  M. Kennemer,et al.  Resequencing of Nicotinic Acetylcholine Receptor Genes and Association of Common and Rare Variants with the Fagerström Test for Nicotine Dependence , 2010, Neuropsychopharmacology.

[25]  Tariq Ahmad,et al.  Meta-analysis and imputation refines the association of 15q25 with smoking quantity , 2010, Nature Genetics.

[26]  Ming D. Li,et al.  Genome-wide meta-analyses identify multiple loci associated with smoking behavior , 2010, Nature Genetics.

[27]  C. Gieger,et al.  Sequence variants at CHRNB3–CHRNA6 and CYP2A6 affect smoking behavior , 2010, Nature Genetics.

[28]  T. Dragani,et al.  Nicotine dependence may link the 15q25 locus to lung cancer risk. , 2010, Carcinogenesis.

[29]  L. Bizarro,et al.  Pharmacogenetics of smoking cessation therapy , 2009, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[30]  L. Bierut.  Convergence of genetic findings for nicotine dependence and smoking related diseases with chromosome 15q24-25. , 2010, Trends in pharmacological sciences.

[31]  C. Gieger,et al.  Sequence variants at CHRNB 3 – CHRNA 6 and CYP 2 A 6 affect smoking behavior , 2010 .

[32]  J. Samet,et al.  Global Economic and Health Benefits of Tobacco Control: Part 1 , 2009, Clinical pharmacology and therapeutics.

[33]  L. Bierut,et al.  Variants Weakly Correlated with CHRNA5 D398N Polymorphism Should be Considered in Transcriptional Deregulation at the 15q25 Locus Associated with Lung Cancer Risk , 2009, Clinical Cancer Research.

[34]  Jie Wu.  Understanding of nicotinic acetylcholine receptors , 2009, Acta Pharmacologica Sinica.

[35]  Scott F. Saccone,et al.  Genetic variation in the CHRNA5 gene affects mRNA levels and is associated with risk for alcohol dependence , 2009, Molecular Psychiatry.

[36]  Tatiana Foroud,et al.  Variants in nicotinic receptors and risk for nicotine dependence. , 2008, The American journal of psychiatry.

[37]  Christina N. Lessov-Schlaggar,et al.  Genetics of nicotine dependence and pharmacotherapy. , 2008, Biochemical pharmacology.

[38]  R. J. Mather,et al.  Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid , 2007, Neuropharmacology.

[39]  R. Hurst,et al.  Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. , 2007, Neuropharmacology.

[40]  A. Morice,et al.  Breath carbon monoxide as an indication of smoking habit. , 2000, Chest.

[41]  R. Lukas,et al.  Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. , 1999, The Journal of pharmacology and experimental therapeutics.

[42]  J. Palca.  Nicotine addiction , 1988, Nature.